Wilson Sonsini Goodrich & Rosati advised JURA Bio on both the financing transaction and the collaboration agreement. JURA Bio announced a research collaboration with Syena, a cell...
JURA Bio’s $16.1 Million Financing and Replay Collaboration
PSG’s Growth Investment in 4me
Wilson Sonsini Goodrich & Rosati advised 4me on the transaction. 4me®, a SaaS-based IT Service Management (ITSM) and Enterprise Service Management (ESM) software vendor, has announced...
ThayerMahan’s $30 Million Series C Round
Wilson Sonsini Goodrich & Rosati advised ThayerMahan on the transaction. ThayerMahan, a world leader in autonomous maritime surveillance solutions, announced the closing of a $30 million...
Tenaya Therapeutics’ $75 Million Shares Offering
Wilson Sonsini Goodrich & Rosati advised Tenaya on the deal, while Davis Polk advised the joint book-running managers and representatives of the several underwriters. Clinical stage...
Arcellx’s $112 Million Public Offering
Wilson Sonsini advised Arcellx on the deal. Arcellx, a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other...
Aramis Biosciences’ $10.5 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Aramis Biosciences on the deal. Aramis Biosciences, a clinical-stage immuno-ophthalmology biopharmaceutical company, announced its launch and the completion of a...
Forge Biologics’ $120 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised RA Capital Management on the deal. Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced the closing of...
Perrone Robotics’ $10 Million Financing
Wilson Sonsini Goodrich & Rosati advised Perrone Robotics on the deal. CapStone Holdings, a business incubator and investment group, announced a $10 million equity investment in...